AC 262271
Alternative Names: AC-262271Latest Information Update: 28 May 2018
Price :
$50 *
At a glance
- Originator ACADIA Pharmaceuticals
- Class Antiglaucomas; Small molecules
- Mechanism of Action Muscarinic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Glaucoma
Most Recent Events
- 28 May 2018 No recent reports of development identified for phase-I development in Glaucoma in USA
- 12 May 2016 Phase I development is ongoing in USA
- 30 Sep 2015 Allergan terminates collaboration agreement with ACADIA Pharmaceuticals for development of muscarinic therapeutics for Glaucoma (ACADIA Pharmaceuticals 10-Q, September 2015)